NZ569507A - Viral hepatitis treatment using nitazoxanide or tizoxanide - Google Patents

Viral hepatitis treatment using nitazoxanide or tizoxanide

Info

Publication number
NZ569507A
NZ569507A NZ569507A NZ56950707A NZ569507A NZ 569507 A NZ569507 A NZ 569507A NZ 569507 A NZ569507 A NZ 569507A NZ 56950707 A NZ56950707 A NZ 56950707A NZ 569507 A NZ569507 A NZ 569507A
Authority
NZ
New Zealand
Prior art keywords
interferon
patient
nitazoxanide
weeks
treatment
Prior art date
Application number
NZ569507A
Other languages
English (en)
Inventor
Jean-Francois Rossignol
Original Assignee
Romark Lab Lc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Romark Lab Lc filed Critical Romark Lab Lc
Publication of NZ569507A publication Critical patent/NZ569507A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
NZ569507A 2006-01-09 2007-01-09 Viral hepatitis treatment using nitazoxanide or tizoxanide NZ569507A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75703606P 2006-01-09 2006-01-09
PCT/US2007/000574 WO2007081974A2 (en) 2006-01-09 2007-01-09 Viral hepatitis treatment

Publications (1)

Publication Number Publication Date
NZ569507A true NZ569507A (en) 2011-11-25

Family

ID=38257004

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ569507A NZ569507A (en) 2006-01-09 2007-01-09 Viral hepatitis treatment using nitazoxanide or tizoxanide

Country Status (17)

Country Link
US (3) US8633230B2 (https=)
EP (1) EP1976516B9 (https=)
JP (2) JP5185826B2 (https=)
CN (1) CN101448497B (https=)
AP (1) AP2907A (https=)
AU (1) AU2007204963B2 (https=)
BR (1) BRPI0706379A2 (https=)
CA (1) CA2636527C (https=)
DK (1) DK1976516T3 (https=)
EA (1) EA015560B1 (https=)
ES (1) ES2422556T3 (https=)
IL (1) IL192548A (https=)
MX (1) MX2008008723A (https=)
NZ (1) NZ569507A (https=)
UA (1) UA100840C2 (https=)
WO (1) WO2007081974A2 (https=)
ZA (1) ZA200806310B (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006235490A1 (en) * 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
CA2636527C (en) 2006-01-09 2016-05-17 Romark Laboratories, L.C. Viral hepatitis treatment
WO2009015336A2 (en) * 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
SI2395840T1 (sl) * 2009-02-13 2020-08-31 Romark Laboratories, L.C. Farmacevtske formulacije nitazoksanida z nadzorovanim sproščanjem
EP2408770B1 (en) 2009-03-20 2014-11-05 University Of Virginia Patent Foundation Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials
NZ596538A (en) 2009-05-12 2014-04-30 Romark Lab Lc Haloalkyl heteroaryl benzamide compounds
CN108042535A (zh) 2009-06-26 2018-05-18 罗马克实验室有限公司 用于治疗流感的化合物和方法
US9333193B2 (en) 2010-09-20 2016-05-10 University Of Virginia Patent Foundation Compositions and methods for treating tuberculosis
CN107096032A (zh) 2011-05-16 2017-08-29 罗马克实验室有限公司 在有需要的对象中刺激免疫应答的方法
CN102805747B (zh) * 2011-06-01 2013-09-18 漳州片仔癀药业股份有限公司 2-(4-吗啉苯胺)-6-环己基氨基嘌呤及其药学上可接受的盐在制药中的用途
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
WO2013110975A1 (es) 2012-01-27 2013-08-01 Siegfried Rhein S.A. De C.V. Composición de nitazoxanida mejorada y proceso para prepararla
MX2017006083A (es) 2014-11-11 2017-11-08 Romark Laboratories Lc Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma.
WO2016123073A1 (en) 2015-01-26 2016-08-04 Children's Medical Center Corporation Treatment of infectious diseases
PT3436074T (pt) 2016-03-31 2020-08-21 Romark Laboratories Lc Compostos tiazolida para tratamento de infeções virais
JP2019513762A (ja) * 2016-04-11 2019-05-30 ジェンフィＧｅｎｆｉｔ 胆汁うっ滞及び線維症の処置方法
JP6894923B2 (ja) * 2016-04-11 2021-06-30 ジェンフィＧｅｎｆｉｔ 胆汁うっ滞性及び線維性の疾患の処置方法
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
WO2018140504A1 (en) 2017-01-24 2018-08-02 Patel Manoj K Compositions and methods for blocking sodium channels
US11033534B2 (en) * 2017-01-27 2021-06-15 Genfit Pharmaceutical compositions for combination therapy
WO2018167103A1 (en) * 2017-03-13 2018-09-20 Genfit Pharmaceutical compositions for combination therapy
WO2018195035A1 (en) 2017-04-18 2018-10-25 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase a3
JP7365054B2 (ja) * 2017-11-17 2023-10-19 ケスター，ヒューバート リンパ管平滑筋腫症及びその他の疾患に使用するための［２－［（５－ニトロ－１，３－チアゾール－２－イル）カルバモイル］フェニル］エタノエート
CN109364067B (zh) * 2018-11-17 2020-07-28 王海玲 一种化合物在制备提高血脑屏障通透性药物中的用途
CA3130713A1 (en) 2019-04-09 2020-10-15 Peggy Parroche Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammation
WO2021016543A1 (en) * 2019-07-25 2021-01-28 Romark Laboratories L.C. Antiviral combinations of thiazolide compounds
CN111012788B (zh) * 2019-12-12 2021-01-15 武汉职业技术学院 硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用
US20230303504A1 (en) 2020-07-20 2023-09-28 Romark Laboratories, L.C. Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine
MX2023002208A (es) 2020-08-24 2023-05-17 Romark Laboratories Lc Uso de tiazolidas contra los coronavirus.
CN114259492A (zh) * 2021-12-21 2022-04-01 中以海德人工智能药物研发股份有限公司 硝唑尼特在治疗乙肝中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) * 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1440212A (en) * 1973-08-29 1976-06-23 Phavic Sprl Derivatives of 2-phenoxyacetamido-5-nitrothiazoles
US4315018A (en) * 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
US5387598A (en) * 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5578621A (en) * 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
PL186504B1 (pl) 1994-04-13 2004-01-30 Romark Lab Pochodne benzamidowe i kompozycje farmaceutyczne zawierające te pochodne
US5859038A (en) * 1994-09-08 1999-01-12 Romark Laboratories, L.C. Method for treatment of helicobacter pylori infections
MX9604483A (es) * 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5965590A (en) * 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US5968961A (en) * 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5856348A (en) * 1994-09-08 1999-01-05 Romark Laboratories, L.C. Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
CN100515420C (zh) * 1997-05-07 2009-07-22 罗马克实验室有限公司 脱乙酰基硝噻醋柳胺和硝噻醋柳胺的药用组合物
US5935591A (en) * 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
AU766597B2 (en) * 1998-05-15 2003-10-16 Schering Corporation Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis C infection
US5925622A (en) * 1998-07-13 1999-07-20 Romark Laboratories, L.C. Synthesis of aryl glucuronide of 2-hydroxy-N- (5-nitro-2-thiazolyl) benzamide, and pharmaceutical compositions comprising same
US6180136B1 (en) * 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
US6340696B1 (en) * 1999-03-31 2002-01-22 The Procter & Gamble Company Viral treatment
US7125568B2 (en) * 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
EP1562617B1 (en) 2002-10-29 2006-12-20 Council of Scientific and Industrial Research New use of pipataline
US7081260B2 (en) * 2002-10-29 2006-07-25 Council Of Scientific And Industrial Research α-Glucosidase inhibitors from a natural source
EA200501524A1 (ru) * 2003-03-28 2006-06-30 Сентокор, Инк. Антитела против амилоида, композиции, способы и применения
WO2005049065A2 (en) * 2003-11-19 2005-06-02 Rigel Pharmaceuticals, Inc. Synergistic combinations of dihaloacetamide with interferon or ribavirin for treatment hcv infections
UA90864C2 (en) * 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
US20060194853A1 (en) * 2004-10-08 2006-08-31 Rossignol Jean F Alkyl benzamides
AU2006235490A1 (en) 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
CA2636527C (en) 2006-01-09 2016-05-17 Romark Laboratories, L.C. Viral hepatitis treatment
SI2395840T1 (sl) * 2009-02-13 2020-08-31 Romark Laboratories, L.C. Farmacevtske formulacije nitazoksanida z nadzorovanim sproščanjem

Also Published As

Publication number Publication date
CA2636527A1 (en) 2007-07-19
JP2009522371A (ja) 2009-06-11
US20070167504A1 (en) 2007-07-19
EA015560B1 (ru) 2011-08-30
CN101448497A (zh) 2009-06-03
EP1976516A2 (en) 2008-10-08
DK1976516T3 (da) 2013-07-15
EA200870164A1 (ru) 2008-12-30
US8633230B2 (en) 2014-01-21
US20140112888A1 (en) 2014-04-24
UA100840C2 (ru) 2013-02-11
MX2008008723A (es) 2008-09-26
EP1976516A4 (en) 2009-11-11
ES2422556T3 (es) 2013-09-12
IL192548A0 (en) 2009-02-11
EP1976516B9 (en) 2013-10-30
USRE47404E1 (en) 2019-05-28
JP2010070566A (ja) 2010-04-02
ZA200806310B (en) 2009-12-30
WO2007081974A2 (en) 2007-07-19
EP1976516B1 (en) 2013-04-24
AP2008004550A0 (en) 2008-08-31
IL192548A (en) 2015-08-31
HK1123733A1 (en) 2009-06-26
AU2007204963B2 (en) 2012-09-27
AP2907A (en) 2014-05-31
US9107913B2 (en) 2015-08-18
CA2636527C (en) 2016-05-17
CN101448497B (zh) 2013-07-10
AU2007204963A1 (en) 2007-07-19
BRPI0706379A2 (pt) 2011-03-22
JP5185826B2 (ja) 2013-04-17
WO2007081974A3 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
USRE47404E1 (en) Viral hepatitis treatment
JP2009522371A5 (https=)
WO2006096285A2 (en) Compositions and methods for treating or preventing flaviviridae infections
CN102711686A (zh) 含有低甲基化试剂以及组蛋白脱乙酰基酶抑制剂的药物组合物
KR101628448B1 (ko) 암 치료에 사용하기 위한 베무라페닙 및 인터페론을 포함하는 병용 요법
TW201922256A (zh) 治療淋巴樣惡性疾病之方法
CN120284929A (zh) 用于在已经经历造血干细胞移植的患者中抑制血液恶性肿瘤复发的活性剂
CA2721728A1 (en) Treatment of inflammatory bowel disease with 6-mercaptopurine
HK1123733B (en) Viral hepatitis treatment
CN104114182A (zh) 罗米地辛和5-阿扎胞苷在治疗淋巴瘤中的应用
US7728033B2 (en) Mycophenolate mofetil in diabetic nephropathy
AU2024354382A1 (en) Myt1 inhibitors for the treatment of cancers harboring replication stress mutations
WO2025074271A1 (en) Myt1 inhibitors for the treatment of cancers harboring replication stress mutations
EP1656941A1 (en) Compositions for the treatment of diabetic nephropathy
KR20220082862A (ko) 혈액 악성 종양을 치료하기 위한 병용 요법
EP2450051A1 (en) Medicinal agent and method for treatment of intractable chronic hepatitis c
NZ622752B2 (en) Romidepsin and 5 - azacitidine for use in treating lymphoma
HK1185808B (en) Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 JAN 2017 BY RENEWALS TEAM

Effective date: 20140124

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JAN 2018 BY COMPUTER PACKAGES INC

Effective date: 20161220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JAN 2019 BY COMPUTER PACKAGES INC

Effective date: 20180518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JAN 2020 BY COMPUTER PACKAGES INC

Effective date: 20181218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JAN 2021 BY COMPUTER PACKAGES INC

Effective date: 20191218

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 JAN 2022 BY COMPUTER PACKAGES INC

Effective date: 20210130

LAPS Patent lapsed